Search PubMed⌕ Search

Biomedical subjects

D Rigal

Publications and source records attributed to D Rigal.

At least 127 records · Page 7Linked to original sources
PubMed1986

Establishment of human cell lines producing anti-D monoclonal antibodies: identification of Rhesus D antigen.

Two cell lines producing monoclonal antibodies have been established from peripheral blood of a negative Rhesus blood donor which has been immunized with positive Rhesus red blood cells. Two monoclonal antibodies Co II 8.8 and Co II 7.12 have been selected. Both are IgG1 antibodies, but recognize different epitopes on the Rhesus D antigen, apparently associated with different subunits of the D antigen. Thus the Co II 8.8, like the positive serum, immunoprecipitates an antigen of a relative molecular weight of 33 kDa, while the Co II 7.12 recognizes an antigen of Mr 42 kDa.

Antibodies, Monoclonal↗
PubMed1986

[Anti-fibronectin autoantibodies in systemic lupus erythematosus, rheumatoid polyarthritis, and various viral or bacterial infectious diseases].

A micro-enzyme linked immunosorbent assay (ELISA) aimed at detecting anti-fibronectin (anti-Fn) antibodies has been developed and standardized. Fifty sera from systemic lupus erythematosus (SLE), 50 from rheumatoid arthritis (RA) patients, as well as 200 sera from patients with bacterial or viral infections were assayed for the presence of anti-Fn autoantibodies. The IgG fractions of three representative positive sera (1 SLE, 1 RA and 1 streptococcal endocarditis) were digested with pepsin and the resulting F(ab')2 fragment assayed in the test. The presence of the anti-Fn activity in these fragments as well as lack of correlation in individual sera between the level of anti-Fn (as determined by ELISA) and that of Ig or immune complexes, suggest that our anti-Fn autoantibodies are indeed detected in our assay. The meaning of these antibodies, which were also found with bacterial and viral infections is discussed within the frame of the fibronectin biological properties.

Arthritis, Rheumatoid↗
PubMed1986

[Value of plasma fibronectin in pediatric intensive care].

This work was undertaken to demonstrate the pathophysiologic and prognostic value of plasma fibronectin measurement in critically ill children. Fibronectin was measured by laser-nephelometry in 25 children (group 1) whose ages ranged from 1 month to 12 years (mean: 13.8 months). All presented with severe infections. The control group consisted of 16 children with various benign disorders, whose ages ranged from 3 months to 13 years (mean: 3.6 years). Fibronectin plasma levels in group 1 (mean: 0.16 g/l +/- 0.08) and in the control group (mean: 0.28 +/- 0.10) were significantly different (alpha less than 0.001). The initial concentration and the kinetics of this protein during evolution seem to have a good diagnostic and prognostic value in severe infections in children.

Bacterial Infections↗
PubMed1985

[Evaluation of erythrocyte survival by the determination of glycosylated hemoglobin. Clinical value].

In normoglycaemic subjects the haemoglobin glycosylation rate primarily depends on duration of erythrocyte life. Measurements of glycosylated haemoglobin therefore can be used to evaluate erythrocyte life. Indeed, glycosylated haemoglobin is significantly reduced (p less than 0.001) in patients with autoimmune haemolytic anaemia or Minkowski-Chauffard syndrome as compared with patients with non-haemolytic anaemia. In addition, there is a strong correlation (r = 0.92) in non-diabetic subjects between the level of glycosylated haemoglobin and the percentage of daily haemolysis, as determined by a method using 51 Cr-labelled antologous red cells.

Anemia↗
PubMed1985

Transplant of rhesus-positive bone marrow in a rhesus-negative woman having anti-rhesus D alloantibodies.

A woman affected by acute myeloblastic leukemia was grafted with HLA A, B and D compatible rhesus-positive bone marrow from her brother. Before grafting, she had anti-D alloantibodies (1/512 IAT, 2.9 micrograms/ml). To prevent the destruction of donor red blood cells, four plasma exchanges and a conditioning regimen (total-body irradiation 800 rad, cyclophosphamide, methotrexate) were carried out to decrease anti-D from 2.9 to less than 0.02 micrograms/ml on day 0. The anti-D level was 0.8 micrograms/ml on day 12 and was decreased to 0.2 micrograms/ml by eight plasma exchanges until day 35. Anti-D antibodies were undetectable with Lalezari's technique on day 45. Engraftment was obtained on day 25 (3,000 leukocytes/mm3 and 50% erythroblasts in bone marrow). The patient died from aspergillosis and graft-versus-host disease on day 54. This observation shows that an engraftment of rhesus-positive bone marrow in a recipient with anti-D antibody is possible.

Adult↗
PubMed1984

[A case of hemolytic disease in a newborn associated with anti-Wra (WRIGHT) antibodies].

A french woman delivered a third full-term male baby who had a strongly positive direct antiglobulin test. During the pregnancy and after the delivery, the woman had a negative irregular antibody screening test using standard red blood cell panels. The compatibility testing between the mother's serum and the father's red blood cells was strongly positive and the antibody was identified as an anti-Wra. The baby developed a mild hyperbilirubinemia and recovered without treatment. This child was probably responsible for his mother's immunization since the two previous children were Wra negative and the mother had no history of blood transfusion or abortion.

Antibodies↗
PubMed1984

Improvement of enzyme-linked antiglobulin test by using an antiglobulin linked to glucose oxidase: description of the technique.

The classic enzyme-linked antiglobulin test (ELAT) used to detect and quantify the amount of IgG antibodies on red blood cells (RBC) is sensitive to hemolysis and erythrocyte enzymatic activities. We describe a new ELAT by using glucose oxidase (GO) linked to antihuman IgG. The optical density base line of GO-ELAT, alkaline phosphatase-ELAT and peroxidase-ELAT were, respectively, 0.180, 0.350 and 0.550. This very low baseline of GO-ELAT was due to the absence of hemolysis (the pH of the GO substrate is 6.5). This technique is ten times more sensitive than the indirect antiglobulin test and detects up to 1 ng/ml of anti-D alloantibodies. Additional advantages of the technique are (1) there is no intrinsic GO enzyme in RBC, and (2) it is not necessary to fix the RBC.

Alkaline Phosphatase↗
PubMed1984

[Effects of cyaninoside chloride and Heleniene on mesopic and scotopic vision in myopia and night blindness].

A controlled, clinical trial, comparing cyaninoside chloride and Heleniene , was conducted on 31 out-patients suffering from functional disturbances of vision in low-luminance conditions. The evolution of photopic and mesopic visual acuities, electro- oculograms and adapto -electroretinograms was assessed for both treatment groups and controls. Both agents significantly improved photopic visual acuity (p less than 0.05). Only cyaninoside chloride treatment improved visual functions related to mesopic and scotopic vision (p less than 0.01). There were also significant differences between the two treatment groups regarding the velocity of visual adaptation in adapto -electroretinography. This study thus demonstrates the therapeutic value of cyaninoside chloride for the treatment of functional disturbances of mesopic and scotopic vision, especially in night blindness and myopia.

Adaptation, Ocular↗
PubMed1984

[Fetomaternal blood incompatibility: the situation in 1983].

56 cases of allo-immunization were collected over a period of 4 1/2 years, i.e. 4.3 per 1 000 births. The authors analyse the aetiologies of these cases of allo-immunization and the therapeutic indications for the more severe cases. They discuss the indications for plasmapheresis, in utero transfusion and premature extraction of the fetus. Five deaths were recorded from this series of 56 births.

Blood Transfusion, Intrauterine↗
PubMed1984

[Hemolytic disease of the newborn caused by maternal allo-immunization against erythrocyte antigens other than A, B and rhesus D].

The authors analyse numerous publications dealing with hemolytic disease of the newborn due to erythrocyte antigens other than A, B and Rhesus D. They emphasize the frequency of these diseases and the clinical presentation according to the antibody specificity. Finally, they suggest a practical management to treat these hemolytic diseases of the newborn.

Blood Group Antigens↗
PubMed1984

[The diagnosis of Gougerot-Sjorgen syndrome in rheumatology. I. Evaul ation of the principal complementary examinations].

The examination of a patient with Sjögren's syndrome includes evaluation of the eye, the buccal cavity, and a search for certain factors in the blood. Schirmer's blotting-paper test is a good test but is not specific. In addition, a decreased amount of tearing is difficult to interpret after the age of 45. Slit-lamp examination (rose bengal and fluorescein) yields lesions which confirm keratoconjunctivitis due to decreased tearing. The buccal component is difficult to evaluate. A biopsy of the buccal mucosa gives the best results with minimum risk and expense. Nucleotide scanning is sensitive, but less specific. Salivary flow decreases with age. After 60 years of age this decrease can not be interpreted. The chemical composition of tears or of saliva is promising, but it is not yet a part of the usual diagnostic work-up. Of the available laboratory tests, anti-SS-A antibodies and/ or anti-SS-B antibodies are of value, but they are not found consistently.

Humans↗
PubMed1984

[124 cases of hemolytic diseases in newborn infants other than ABO and Rhesus D observed in the Blood Transfusion Center of Lyon between 1970 and 1982].

Between 1970 and 1982, 124 cases of hemolytic diseases of the newborn due to antigens other than A, B and Rhesus-D were observed in the Blood Bank of Lyon (France). These cases represent 10,3% of all the hemolytic diseases of the newborn (ABO excluded). This percentage has raised during this period: 2,1% in 1970 until 39,2% in 1982. The variation is due both to the fall of the Rhesus-D hemolytic diseases and to the raise of non Rhesus-D hemolytic diseases. The alloantibody titer is not a good criteria in order to predict the anemia level of the newborn but the amniotic fluid delta OD 450 is satisfactory whatever the alloimmunisation is.

Erythroblastosis, Fetal↗
PubMed1984

[Hemolytic disease of newborn infants caused by anti-Diego antibodies].

A native Cambodian woman delivered a third full-term female baby who had a strongly positive direct antiglobulin test. During the pregnancy and after the delivery, the woman had a negative irregular antibody screening test using standard red blood cell panels, but the indirect antiglobulin test between the mother's serum and the father's red blood cells was strongly positive. The antibody could be eluted from the baby's red blood cells and its was identified as an anti-Dia (Diegoa). The child developed a mild hyperbilirubinemia and recovered without treatment.

Blood Group Antigens↗